BRPI0517932A8 - Muteína humana de beta-interferon, polinucleotídeo, vetor de expressão, célula animal, método para preparação de referida muteína e composição farmacêutica compreedendo a mesma - Google Patents

Muteína humana de beta-interferon, polinucleotídeo, vetor de expressão, célula animal, método para preparação de referida muteína e composição farmacêutica compreedendo a mesma

Info

Publication number
BRPI0517932A8
BRPI0517932A8 BRPI0517932A BRPI0517932A BRPI0517932A8 BR PI0517932 A8 BRPI0517932 A8 BR PI0517932A8 BR PI0517932 A BRPI0517932 A BR PI0517932A BR PI0517932 A BRPI0517932 A BR PI0517932A BR PI0517932 A8 BRPI0517932 A8 BR PI0517932A8
Authority
BR
Brazil
Prior art keywords
mutein
beta
polynucleotide
preparing
pharmaceutical composition
Prior art date
Application number
BRPI0517932A
Other languages
English (en)
Inventor
Kee Shin Young
Tai Kim Ji
Kyoung So Moon
Min Lee Jong
Yang Ji-Hye
Uk Yoo Ji
Ho Byun Tae
Kyu Oh Han
Chul Yoon Ho
Soo Ahn Ji
Song Kyung
Ho Jin Jae
Original Assignee
Kee Shin Young
Referencebiolabs Co Ltd
Abion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kee Shin Young, Referencebiolabs Co Ltd, Abion Inc filed Critical Kee Shin Young
Publication of BRPI0517932A publication Critical patent/BRPI0517932A/pt
Publication of BRPI0517932A8 publication Critical patent/BRPI0517932A8/pt
Publication of BRPI0517932B1 publication Critical patent/BRPI0517932B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

MUTEÍNA HUMANA DE BETA-INTERFERON. A presente invenção refere-se a uma muteína humana de beta-interferon. Em particular, a presente invenção se refere à muteína humana de beta-interferon dotada de uma ou duas cadeias adicionais de açúcar comparado com o beta-interferon natural de origem humana.
BRPI0517932-7A 2004-11-02 2005-11-02 Muteína humana de beta-interferon, polinucleotídeo, vetor de expressão, célula animal, método para preparação de referida muteína e composição farmacêutica compreedendo a mesma BRPI0517932B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020040088196A KR100781666B1 (ko) 2004-11-02 2004-11-02 인간 인터페론-베타 변이체
KR10-2004-0088196 2004-11-02
PCT/KR2005/003665 WO2006049423A1 (en) 2004-11-02 2005-11-02 Human interferon-beta mutein

Publications (3)

Publication Number Publication Date
BRPI0517932A BRPI0517932A (pt) 2008-10-21
BRPI0517932A8 true BRPI0517932A8 (pt) 2018-05-02
BRPI0517932B1 BRPI0517932B1 (pt) 2021-10-19

Family

ID=36319397

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517932-7A BRPI0517932B1 (pt) 2004-11-02 2005-11-02 Muteína humana de beta-interferon, polinucleotídeo, vetor de expressão, célula animal, método para preparação de referida muteína e composição farmacêutica compreedendo a mesma

Country Status (11)

Country Link
US (1) US8101716B2 (pt)
EP (1) EP1809661B1 (pt)
JP (1) JP4637913B2 (pt)
KR (1) KR100781666B1 (pt)
CN (1) CN101111519B (pt)
AT (1) ATE509951T1 (pt)
BR (1) BRPI0517932B1 (pt)
DK (1) DK1809661T3 (pt)
ES (1) ES2369088T3 (pt)
PT (1) PT1809661E (pt)
WO (1) WO2006049423A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2576030A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
MX2009011870A (es) 2007-05-02 2009-11-12 Ambrx Inc Polipeptidos de interferon beta modificados y usos de los mismos.
CN102260344A (zh) * 2010-05-26 2011-11-30 重庆富进生物医药有限公司 缺失型人β干扰素及其重组制备
JP6153470B2 (ja) 2011-10-01 2017-06-28 株式会社糖鎖工学研究所 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物
ES2687801T3 (es) 2013-03-29 2018-10-29 Glytech, Inc. Polipéptido presentando cadenas de azúcares sialiladas unidas al mismo
ES2736503T3 (es) * 2014-04-04 2020-01-02 Ares Trading Sa Nuevos análogos de la proteína IFN beta
WO2016013911A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 페길화된 인터페론 -베타 변이체
WO2016013697A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체
KR101838919B1 (ko) * 2015-03-03 2018-03-15 에이비온 주식회사 인간 인터페론-베타 변이체가 접합된 면역사이토카인 및 이의 제조방법
US20210009720A1 (en) * 2015-03-03 2021-01-14 Genopharm Inc. Human interferon-beta variant conjugated immunocytokine and method for preparing same
WO2016163764A2 (ko) * 2015-04-07 2016-10-13 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
KR102666000B1 (ko) 2016-07-29 2024-05-14 서울대학교 산학협력단 cFLIP siRNA를 포함하는 인터페론 베타 저항성 암 질환 치료용 또는 감작용 조성물
KR101943160B1 (ko) * 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
KR101955366B1 (ko) 2017-06-02 2019-03-07 인제대학교 산학협력단 인터페론 베타-엘라스틴 재조합 단백질 및 이의 생산방법
CN108117595B (zh) * 2018-02-28 2020-06-26 中国科学院微生物研究所 一种犬α干扰素的制备及其应用
KR20210021861A (ko) * 2019-08-19 2021-03-02 (주)제노팜 사람 표피성장인자수용체 2 양성 암을 치료하기 위한 인터페론-베타 변이체 면역사이토카인의 용도 및 환자 선별 방법
US20240270807A1 (en) * 2020-04-29 2024-08-15 Genopharm Inc. Recombinant protein having fused interferon-beta mutein and antibody, and pharmaceutical composition comprising same
MX2022013662A (es) * 2020-04-29 2023-02-01 Abion Inc Variante del interferon-beta humano con doble mutacion y metodo para mejorar la estabilidad de la variante del interferon-beta humano.
EP4292604A4 (en) * 2021-01-13 2024-12-18 Abion Inc. METHOD OF PROPHYLACTIC ADMINISTRATION AGAINST A RESPIRATORY VIRUS, COMPRISING THE ADMINISTRATION OF INTERFERON BETA TO A SUBJECT POTENTIALLY INFECTED WITH A RESPIRATORY VIRUS
KR20240118230A (ko) * 2023-01-26 2024-08-05 에이비온 주식회사 인터페론 베타 건조 분말 제제 및 이의 제조방법
AU2024341598A1 (en) * 2023-09-12 2026-04-23 Heligenics Inc. Engineered interferon-beta proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
DE19717864C2 (de) 1997-04-23 2001-05-17 Fraunhofer Ges Forschung Humanes rekombinantes Interferon-beta, Verfahren zu seiner Herstellung und seine Verwendung
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
EP1549675B1 (en) 2002-08-31 2008-02-13 CJ Corp Glycosylated human interferon alpha isoform
AU2003277088A1 (en) * 2002-10-01 2004-04-23 Xencor, Inc Interferon variants with improved properties
KR100541850B1 (ko) * 2003-03-31 2006-01-11 삼성정밀화학 주식회사 인간 인터페론-베타 변이체 및 그의 제조방법

Also Published As

Publication number Publication date
KR100781666B1 (ko) 2007-12-03
DK1809661T3 (da) 2011-09-05
CN101111519A (zh) 2008-01-23
EP1809661B1 (en) 2011-05-18
WO2006049423A1 (en) 2006-05-11
PT1809661E (pt) 2011-09-05
BRPI0517932A (pt) 2008-10-21
US20100003721A1 (en) 2010-01-07
ES2369088T3 (es) 2011-11-25
JP4637913B2 (ja) 2011-02-23
BRPI0517932B1 (pt) 2021-10-19
ATE509951T1 (de) 2011-06-15
EP1809661A4 (en) 2008-02-06
JP2008518631A (ja) 2008-06-05
EP1809661A1 (en) 2007-07-25
CN101111519B (zh) 2012-11-07
US8101716B2 (en) 2012-01-24
KR20060039132A (ko) 2006-05-08

Similar Documents

Publication Publication Date Title
BRPI0517932A8 (pt) Muteína humana de beta-interferon, polinucleotídeo, vetor de expressão, célula animal, método para preparação de referida muteína e composição farmacêutica compreedendo a mesma
CY1122816T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
BRPI0516857A (pt) dispositivos biomédicos que contêm copolìmeros de bloco anfifìlico
NO20083940L (no) Fremgangsmater for redusering av proteinaggregering
BRPI0816097A2 (pt) composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
CY1117312T1 (el) Θεραπευτικη αγωγη συνουκλεϊνοπαθειων
DK2227539T3 (da) Sammensætning til menneske- og/eller dyreernæring, anvendelser deraf og gær
BRPI0813311A2 (pt) Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica.
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
EP2130794A4 (en) PURE CHLORINE DIOXIDE SOLUTION AND LIQUID COMPOSITION AND DISPOSABLE COMPOSITION THEREWITH
NO2017002I1 (no) Cobicistat eller farmasøytisk akseptabelt salt derav og atazanavir eller farmasøytisk akseptabelt salt derav, spesielt atazanavirsulfat
BRPI0820952A2 (pt) Composição nutricional enteral líquida, método para prover nutrição a uma pessoa em necessidade da mesma, e, uso simultâneo ou seqüêncial de caseína micelar e caseinato
CR11795A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EP1723804A4 (en) MOBILITY ARCHITECTURE BASED ON THE USE OF PRE-AUTHENTICATION, PRE-CONFIGURATION AND / OR INTERCELLULAR TRANSFER WITHOUT VIRTUAL BREAK
SI1971366T1 (sl) Humana protitelesa anti-il-23, sestavki, postopki in uporabe
NO20085420L (no) Farmasøytisk formulering med fenylefrin og preparater for absorpsjon i tykktarmen
BRPI0815576A2 (pt) Método para produzir uma linha celular que produz uma proteína terapêutica, segunda linha celular transformada com uma segunda seqüência de polinucleotídeos, vetor, cassete de expressão amplificado, linha celular ou sua progênie, e, anticorpo.
ATE496623T1 (de) Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
BRPI0809583A2 (pt) polipeptídeos fgf-21 modificados e seus usos
BRPI0906997A2 (pt) Proteína, uso da proteína combinante ou fragmento da mesma, método para induzir uma resposta imune em um individuo, método para tratar um paceinte, construção de ácido nicleico, vetor de ezpressão o ucélula hospedeira, vacina, anticorpo, e, composição farmaceutica
HRP20150828T8 (hr) Kompozicije i postupci in vitro i in vivo ciljanog oslobađanja lijeka u stanicama sisavaca, preko intaktnih mini-stanica izvedenih iz bakterija
EA201170242A1 (ru) Модифицированные бычьи полипептиды g-csf и их применение
BR112013019083A2 (pt) combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença.
BR122020010601B8 (pt) conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: REFERENCEBIOLABS CO., LTD. (KR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25A Requested transfer of rights approved

Owner name: ABION INC. (KR)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: DESPACHO: PARA QUE A PETICAO NO 870190036018 DE 15/04/2019 POSSA SER ACATADA COMO RECURSOAO ARQUIVAMENTO, O DEPOSITANTE DEVERA REALIZAR O PAGAMENTO DO VALOR DA RETRIBUICAO DEVIDA.

B12C Appeal against dismissal [chapter 12.3 patent gazette]
B11T Dismissal of application maintained [chapter 11.20 patent gazette]
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.20 NA RPI NO 2594 DE 24/09/2020 POR TER SIDO INDEVIDA.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/11/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.